Targeting EP2 Receptor for Drug Discovery: Strengths, Weaknesses, Opportunities, and Threats (SWOT) Analysis
Year: 2023
Type: review
Abstract: ) triggers several physiological and pathological conditions. It mediates signaling through four G-protein coupled receptors, EP1, EP2, EP3, and EP4. Among these, EP2 is expressed throughout the body including the brain and uterus. The functional role of EP2 has been extensively studied using EP2 gene knockout mice, cellular models, and selective small molecule agonists and antagonists for this receptor. The efficacy data from in vitro and in vivo animal models indicate that EP2 receptor is a major proinflammatory mediator with deleterious functions in a variety of diseases suggesting a path forward for EP2 inhibitors as the next generation of selective anti-inflammatory and antiproliferative agents. Interestingly in certain diseases, EP2 action is beneficial; therefore, EP2 agonists seem to be clinically useful. Here, we highlight the strengths, weaknesses, opportunities, and potential threats (SWOT analysis) for targeting EP2 receptor for therapeutic development for a variety of unmet clinical needs.
Source: Journal of Medicinal Chemistry
Author: Thota Ganesh
Institution: Emory University
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,000
Awards: EP2 antagonists as novel anti-epileptogenic agents, G2220215625, G3051903314, Optimization of EP2 Antagonists for Post-Seizure Cognitive Deficits, Optimization of EP2 Antagonists for Post-Seizure Cognitive Deficits, G6253505940, EP2 Antagonist Development for Post-seizure Cognitive Deficits, G9000155382, G9000193994, Development of EP2 Receptor Antagonist to Treat Alzheimer's Disease, Development of EP2 receptor antagonists for suppression of Alzheimer's neuropathology
OpenAlex ID: W4384559600